| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
APOLIPOPROTEIN E GENOTYPE
MessageCollect Monday-Thursday before 1400EST only and not the day before a holiday.
Test Code
LAB00155
Alias/See Also
LAB00155
Mayo TC: APOEG
Frederickson Type III
Dyslipoproteinemia
Dyslipidemia
Dysbetalipoproteinemia
Mayo TC: APOEG
Frederickson Type III
Dyslipoproteinemia
Dyslipidemia
Dysbetalipoproteinemia
CPT Codes
81401
Preferred Specimen
3.0 mL Lavender (EDTA) - Whole Blood
Minimum Volume
1 mL Lavender (EDTA) - Whole Blood
Other Acceptable Specimens
Yellow Top (ACD)
Transport Temperature
Room Temperature
Specimen Stability
Specimen preferred to arrive within 96 hours of draw.
Methodology
Polymerase Chain Reaction (PCR)
Report Available
6-8 days
Limitations
This assay will not detect all of the genetic variants that cause type III hyperlipoproteinemia. Therefore, the absence of a detectable genetic variant does not rule out the possibility that an individual is a carrier of or affected with this disease.
This assay cannot predict or rule out the development of Alzheimer disease in an individual.
Test results should be interpreted in the context of clinical finding, family history, and other laboratory data. Errors in the interpretation of results may occur if information given is inaccurate or incomplete.
Rare variants (ie, polymorphisms) exist that could lease to false-negative and false-positive results. If results obtained do not match the clinical finding, additional tesing should be considered.
In rare cases, DNA alterations of undetermined significance may be identified.
This assay does not identify all of the less common apolipoprotein E alleles. Thus, an individual who appears to be homozygous for e2, e3, or e4 may carry one of the rare allels that cannot be detected by this assay.
This assay cannot predict or rule out the development of Alzheimer disease in an individual.
Test results should be interpreted in the context of clinical finding, family history, and other laboratory data. Errors in the interpretation of results may occur if information given is inaccurate or incomplete.
Rare variants (ie, polymorphisms) exist that could lease to false-negative and false-positive results. If results obtained do not match the clinical finding, additional tesing should be considered.
In rare cases, DNA alterations of undetermined significance may be identified.
This assay does not identify all of the less common apolipoprotein E alleles. Thus, an individual who appears to be homozygous for e2, e3, or e4 may carry one of the rare allels that cannot be detected by this assay.
Clinical Significance
Useful For determining the specific apolipoprotein E (APOE) genotypes in patients with type III hyperlipoproteinemia
Determining the specific apolipoprotein E (APOE) genotypes that may increase risk for amyloid related imaging abnormalities in individuals being treated for Alzheimer disease with B-amyloid-targeting antibodies.
APOE genotyping has been used to assess susceptibility for Alzheimer disease. However, the use of APOE analysis for predictive testing for Alzheimer disease is not currently recommended by the American College of Medical Genetics due to limited clinical utility and poor predictive value.
Determining the specific apolipoprotein E (APOE) genotypes that may increase risk for amyloid related imaging abnormalities in individuals being treated for Alzheimer disease with B-amyloid-targeting antibodies.
APOE genotyping has been used to assess susceptibility for Alzheimer disease. However, the use of APOE analysis for predictive testing for Alzheimer disease is not currently recommended by the American College of Medical Genetics due to limited clinical utility and poor predictive value.
Performing Laboratory
Mayo Clinic Laboratories